Strategic Partnerships ยท South Sudan
Building verified manufacturer relationships and institutional channels to secure quality-assured pharmaceutical supply into the Republic of South Sudan.
Exploring Partnerships with International Manufacturers
Eagles Pharma is actively exploring a strategic distribution partnership with Addii Biotech Pvt. Ltd., India, a reputable pharmaceutical manufacturer recognized for adhering to internationally accepted Good Manufacturing Practice (WHO-GMP) standards.
The ongoing dialogue encompasses the possibility of an exclusive distribution arrangement for the South Sudan market, which would designate Eagles Pharma as the authorized national distributor for Addii Biotech's extensive portfolio of essential therapeutic formulations.
New Delhi / Haryana, India
Navigating pharmaceutical entry into emerging African markets requires compliance rigour, robust storage infrastructure, and trusted local relationships.
We handle end-to-end product dossier compilation in CTD format, sample submissions, and regulatory liaison with the Drug and Food Control Authority of South Sudan.
By establishing closed, audited distribution corridors from manufacturer warehouses to end-point healthcare facilities, we prevent counterfeit infiltration and grey-market leaks.
Deep connectivity with public health institutions, faith-based hospital networks, and international NGOs operating humanitarian health clusters across South Sudan.
Healthcare providers and relief agencies in South Sudan cannot afford supply volatility. Eagles Pharma is formulating institutional partnership frameworks designed to provide security of supply through:
Engage our corporate development team regarding manufacturer, hospital, or institutional collaboration.
Eagles Pharma is a proposed pharmaceutical distribution company in its pre-launch stage in South Sudan.
All potential distribution collaborations, including dialogue with Addii Biotech Pvt. Ltd. (India), are exploratory and subject to final formal agreements, company registration, and regulatory approvals by the Drug and Food Control Authority (DFCA).
Reference: EP-PRQ-2026